Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7317606 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL30135880 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL2036815 | 0.87 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL16233087 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL31090163 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL8297975 | 0.85 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL28712446 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL5913106 | 0.84 | MAPT (0.64) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL11440920 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL4977602 | 0.83 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| CN-104356000-A | Method for preparing 3-nitro-4-methoxy benzoic acid | WUJIANG MEIYAN SANYOU DYESTUFF CHEMICAL CO LTD | 2015-02-18 | — | — | CN | disclosed |
| US-8664272-B2 | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
| US-4243806-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-06 | — | — | US | disclosed |
| US-4206144-A | N,N-Dialkyl-N-aminoalkyl-N-(amino or nitro)phenylalkyl- and N-methyl-N-[3-(amino or nitro)phenoxy-2-hydroxy-1-propyl]-N,N-bis(3-aminopropyl)quaternary ammonium salts | STERLING DRUG INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4179505-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4146558-A | Azo dyestuff intermediate nitro- or aminobenzenes ring-substituted by a quaternized amine alkyl or amino-alkoxy group | STERLING DRUG INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
| US-3897496-A | N,N-dialkyl-N-C8{14 C22-alkyl)-N-3-nitro-4-methoxybenzylammonium chlorides | H.D. ACQUISITION CORP., A CORP. OF DE. | 1975-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | SMN1; SMN2 2859/4885ALDH1A1 630/4885LMNA 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.